French drugmaker Ipsen and US partner Medicis say that the Food and Drug Administration has accepted the firms’ dossier seeking approval for Reloxin, which will be a competitor to Allergan’s Botox.

The FDA has started a review of a Biologics License Application to for use of the botulinum toxin type A product Reloxin in aesthetic indications. The agency’s acceptance of the file has triggered a payment of $25 million to Ipsen and if Reloxin gets approxed, Medicis will pay a further $75 million and market the treatment in the USA.

Ipsen is confident it will get approval given that its botulinum toxin product is already approved in 23 countries. However the US aesthetic sector is thought to be worth up to $400 million, and if Reloxin wins the green light it will be able to claim a substantial portion of the market which is dominated by Botox (also botulinum toxin type A).

Ipsen already sells the product as a treatment for cervical dystonia, under the brandname Dysport, a chronic condition in which the neck is twisted or deviated, and it has also been developed for a wide variety of neuromuscular disorders. The firm also recently filed a BLA for Dysport in cervical dystonia to the FDA.